Stifel Reiterates Buy Rating on Fulcrum Therapeutics (FULC) With $43 PT, Sees Losmapimod Trial as a "Meaningful Binary Catalyst for the Stock"
Tweet Send to a Friend
Stifel analyst Dae Gon Ha reiterated a Buy rating and $43.00 price target on Fulcrum Therapeutics (NASDAQ: FULC), following a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
